Benjamin J. Eckhardt, MD, MS
NYU School of Medicine, Department of Medicine, Division of Infectious Diseases and Immunology - Assistant Professor Medicine
Bellevue Hospital, Department of Medicine, Division of Infectious Diseases and Immunology
Bellevue Hospital, Department of Medicine, Division of Infectious Diseases and Immunology
Email: benjamin.eckhardt@gmail.com
Education
MD, Albert Einstein College of MedicineMS, Clinical Epidemiology and Health Services Research, Cornell University Graduate School of Medical Sciences
BS, Biological and Environmental Engineering, Cornell University
Research Interests
Hepatitis C, HIV, People who inject drugs, Harm reduction BIO
Benjamin Eckhardt received his MD degree from Albert Einstein College of Medicine and Internal Medicine training at NYU within the Primary Care Program. After completing residency, he worked in Rwanda for Partners In Health/Inshuti Mu Buzima with a clinical appointment at Brigham and Women’s Hospital and Harvard Medical School. He returned to New York to complete his fellowship training in Infectious Diseases at Weill Cornell Medical College while concurrently receiving a MS in Clinical Epidemiology and Health Services Research. He joined the faculty at NYU/Bellevue in 2016 with a clinical focus in HIV and hepatitis management.Dr. Eckhardt’s research interest focuses on evaluating models of care to facilitate access, engagement, and retention of active injection drug users in HCV treatment and care.
Projects
Principal Investigator, HCV – Source Patient Identification and Group Overlap Treatment. Completed
Publications
Recent
Kapadia SN, Eckhardt BJ, Leff JA, Fong C, Mateu-Gelabert P, Marks KM, Aponte-Melendez Y, Schackman BR (2022).
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial
Drug and Alcohol Dependence Reports, 5, 100109. doi: 10.1016/j.dadr.2022.100109. PMCID: PMC9836210.
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial
Drug and Alcohol Dependence Reports, 5, 100109. doi: 10.1016/j.dadr.2022.100109. PMCID: PMC9836210.
Finbraten AK, Eckhardt BJ, Kapadia SN, Marks KM (2022).
Rapid treatment initiation for hepatitis C virus infection: Potential benefits, current limitations, and real-world examples
Gastroenterology and Hepatology, 18 (11), 628-638.
Rapid treatment initiation for hepatitis C virus infection: Potential benefits, current limitations, and real-world examples
Gastroenterology and Hepatology, 18 (11), 628-638.
Hrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B (2022).
Factors associated with severe bacterial infections in people who inject drugs: A single-center observational study
Journal of Addiction Medicine [Epub 2022 Oct 18]. doi: 10.1097/ADM.0000000000001099.
Factors associated with severe bacterial infections in people who inject drugs: A single-center observational study
Journal of Addiction Medicine [Epub 2022 Oct 18]. doi: 10.1097/ADM.0000000000001099.
Eckhardt B, Aponte-Melendez Y, Kapadia SN, Mateu-Gelabert P (2022).
Contact tracing in acute hepatitis C: The source patient identification and group overlap therapy proof-of-concept pilot program
Clinical Liver Disease, 20 (2), 72-76. doi: 10.1002/cld.1242. PMCID: PMC9405500.
Contact tracing in acute hepatitis C: The source patient identification and group overlap therapy proof-of-concept pilot program
Clinical Liver Disease, 20 (2), 72-76. doi: 10.1002/cld.1242. PMCID: PMC9405500.
Mateu-Gelabert P, Sabounchi NS, Guarino H, Ciervo C, Joseph K, Eckhardt BJ, Fong C, Kapadia SN, Huang TTK (2022).
Hepatitis C virus risk among young people who inject drugs
Frontiers in Public Health, 10, 835836. doi: 10.3389/fpubh.2022.835836. PMCID: PMC9372473.
Dr. Eckhardt's NYU Langone Profile
Hepatitis C virus risk among young people who inject drugs
Frontiers in Public Health, 10, 835836. doi: 10.3389/fpubh.2022.835836. PMCID: PMC9372473.